Home / Stocks / Valiant Laboratories Ltd
VALIANTLAB

Valiant Laboratories Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹96.84

Change

-1.97 (-1.99%)

Open

₹96.84

Prev. Close

₹98.81

Day High

₹96.84

Day Low

₹96.84

Volume Analysis

Traded

3,348

Delivered

178,511

Delivery %

49.05%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (-2.55%)
  • •Below-average fundamentals quality score (41/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84
Fibonacci ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84
Camarilla ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84 ₹96.84

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+40.8%

1 Week

-9.58%

1 Month

-27.58%

3 Months

+1.15%

6 Months

+25.96%

1 Year

+25.77%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

3.03%

Net margin 4.26% × asset turnover 0.52x × equity multiplier 1.37x

Company Overview

Sector

Healthcare

Market Cap

₹570 Cr

P/E (TTM)

35.2

ROE

-2.55%

Book Value

₹61.2

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Valiant Laboratories Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 41/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-2.55%); below-average fundamentals quality score (41/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

41/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

49

Cash Flow

13

Corporate Governance

56

Momentum

61

Institutional Ownership

20

Business Quality

32

Risk & Volatility

51

Liquidity

29

From Screener.in

  • +Company has reduced debt.
  • +Company is expected to give good quarter
  • −Company has a low return on equity of -2.15% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Copy of Newspaper Publication of Financial Results for quarter and half year ended September 30, 2026.

Board approved audited Q2/H1 FY27 standalone and consolidated results on Nov 2, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 60 41 31 19 21 35 58 47 46 52 92 115 117
Expenses + 61 47 35 21 28 35 54 44 46 53 87 86 112
Operating Profit -1 -6 -5 -2 -7 1 4 2 0 -1 5 29 5
OPM % -2.33% -15.57% -14.81% -12.66% -31.38% 1.76% 6.61% 5.1% 0.17% -1.7% 5.23% 25.38% 4.44%
Other Income + 3 2 3 3 3 2 -2 1 1 1 0 1 0
Interest 0 0 0 0 0 0 0 0 0 1 1 1 1
Depreciation 0 0 1 1 1 1 1 1 1 2 3 3 4
Profit before tax 1 -5 -3 0 -4 2 1 2 0 -3 1 26 1
Tax % 25.47% -30.75% -51.75% 218.75% 21.23% -44.44% 25.53% 25.71% 25.0% 136.12% -68.27% 19.43% 37.31%
Net Profit + 1 -4 -1 -1 -5 2 1 2 0 -7 2 21 0
EPS in Rs 0 -1 0 0 -1 1 0 0 0 -1 0 4 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -32 -43 -66 -63 -64 -13 89 148 115 49 59 146 153

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 334 182 133 237 376
Expenses + 299 190 138 231 338
Operating Profit 35 -8 -5 6 38
OPM % 11.0% -4.6% -3.5% 2.7% 10.0%
Other Income + 5 10 5 2 2
Interest 0 0 0 2 4
Depreciation 2 2 2 6 12
Profit before tax 38 -1 -2 1 25
Tax % 24.0% -142.0% 46.0% 525.0% —
Net Profit + 29 0 -2 -3 16
EPS in Rs 8 0 0 -1 3
Dividend Payout % 0.0% 0.0% 0.0% 0.0% —
Sales growth — -45 -27 78 102

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 68 193 191 257 278
Borrowings + 60 77 122 46 38
Other Liabilities + 52 29 45 107 84
Total Liabilities 213 343 401 464 454
Fixed Assets + 48 50 48 227 226
CWIP 1 43 156 6 6
Investments 34 38 0 26 35
Other Assets + 130 212 197 205 187
Total Assets 213 343 401 464 454
Equity Capital 33 43 43 54 54

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 56 2 1 -10
Cash from Investing Activity + -55 -144 -53 7
Cash from Financing Activity + -1 152 45 2
Net Cash Flow 0 10 -7 -1
Free Cash Flow 18 -44 -112 -45
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 185 -11 25 -147

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 74.94% → 74.94%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 17.54% 21.58% 23.18% 25.06% 25.06% 24.42% 23.97% 25.05% 25.05% 24.87% 25.06% 24.91%
Promoters 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
FII 7.08% 3.48% 1.89% 0.0% 0.0% 0.64% 0.63% 0.02% 0.01% 0.2% 0.0% 0.07%
DII 0.43% 0.0% 0.0% 0.0% 0.0% 0.0% 0.46% 0.0% 0.0% 0.0% 0.0% 0.08%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Valiant Laboratories Ltd (this stock) 570 35.2 1.72 -2.55%
Fabtech Technologies Ltd 609 20.5 1.39 12.0%
Rays Of Belief Limited 615 99.3 4.03 16.1%
Haleos Labs Limited 494 38.1 2.25 8.44%
Wanbury Limited 676 20.3 4.3 76.5%
Medicamen Biotech Limited 407 35.2 1.39 3.95%
Gaudium Ivf N Women H L 740 32.0 4.55 24.6%

Which Mutual Funds Hold Valiant Laboratories Ltd?

Frequently Asked Questions about Valiant Laboratories Ltd

Community Sentiment

What are other investors saying about Valiant Laboratories Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.